Acasunlimab
Based on 1 publication(s) in Google Scholar
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.
For research use only. We do not sell to patients.
- Purity : ≥99.0%
- CAS No.: 2253937-12-9
- Molecular Weight:143.86 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-P99675
IvonescimabPD-1/VEGF Bispecific Antibody -
HY-P991097
PumitamigPD-L1/VEGF-A Antibody -
HY-P9902
PembrolizumabPD-1 Inhibitor -
HY-P9903
NivolumabPD-1 Inhibitor -
HY-P9997
RosnilimabPD-1 Antibody -
HY-P9919
DurvalumabPD-L1 Blocking Antibody -
HY-P99052
TislelizumabPD-1 Inhibitor -
HY-P9978
ToripalimabPD-1 Inhibitor -
HY-108730
AvelumabAnti-PD-L1 Antibody -
HY-P99048
SintilimabPD-1/PD-L1 Inhibitor -
HY-101093
CA-170VISTA/PD-L1 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Acasunlimab
More
Biological Activity
Description
Isotype
Ig(G1-kappa_G1-lambda2)
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFRSF9 & CD274
In Vitro
Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) promotes interactions between dendritic cells and T cells and enhances T-cell activation[1].
Acasunlimab (0.001-1 μM; 48 h; PD-L1+ Tumor Cells) induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell–mediated cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Double knock-in (dKI) transgenic C57BL/6 mice[1]
-
Dosage:5 mg/kg
-
Administration:Intravenous injection; twice weekly for three cycles
-
Result:Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Ig(G1-kappa_G1-lambda2)
.png)
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human 4-1BB/CD137 Protein (ECD, His Tag) can bind Acasunlimab. The EC50 for this effect is 5.74 ng/mL. -
Immobilized Human PD-L1/B7-H1 Protein (ECD) can bind Acasunlimab. The EC50 for this effect is 11.27 ng/mL.
Chemical Information
-
CAS No. 2253937-12-9
-
Appearance Liquid
-
Molecular Weight 143.86 kDa
-
Color Colorless to light yellow
-
SMILES
[Acasunlimab]
-
Synonyms
GEN1046
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Muik A, et, al. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265. [Content Brief]
[2]. Gao Y, et, al. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. FEBS Open Bio. 2022 Dec;12(12):2166-2178. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Acasunlimab Related Classifications
HY-P99419 Related Classifications
Powered by Bioz